ArticleCancer immunology, immunotherapy : CII2013

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

Anna Maria Di Giacomo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.